Strategic Global Advisors LLC Acquires New Position in ICON PLC (ICLR)
Strategic Global Advisors LLC acquired a new position in ICON PLC (NASDAQ:ICLR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 81,574 shares of the medical research company’s stock, valued at approximately $7,977,000. ICON PLC makes up about 2.9% of Strategic Global Advisors LLC’s holdings, making the stock its 6th largest holding. Strategic Global Advisors LLC owned about 0.15% of ICON PLC as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the stock. World Asset Management Inc raised its stake in ICON PLC by 1.8% in the first quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock worth $275,000 after buying an additional 60 shares in the last quarter. IFP Advisors Inc increased its position in shares of ICON PLC by 3.0% during the second quarter. IFP Advisors Inc now owns 2,299 shares of the medical research company’s stock worth $225,000 after purchasing an additional 67 shares in the last quarter. Huntington National Bank increased its position in shares of ICON PLC by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after purchasing an additional 77 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of ICON PLC by 5.0% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 3,537 shares of the medical research company’s stock worth $282,000 after purchasing an additional 168 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in shares of ICON PLC by 20.7% during the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after purchasing an additional 217 shares in the last quarter. 90.62% of the stock is owned by institutional investors.
ICON PLC (ICLR) traded down 0.22% during trading on Friday, hitting $111.34. The company had a trading volume of 224,663 shares. The stock has a market capitalization of $6.02 billion, a price-to-earnings ratio of 22.58 and a beta of 0.61. The firm’s 50 day moving average is $108.18 and its 200-day moving average is $93.43. ICON PLC has a 52-week low of $73.76 and a 52-week high of $117.53.
ICON PLC (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. ICON PLC had a net margin of 15.97% and a return on equity of 28.72%. The firm had revenue of $431.00 million for the quarter, compared to analyst estimates of $430.68 million. During the same period last year, the business earned $1.14 EPS. ICON PLC’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts forecast that ICON PLC will post $5.32 earnings per share for the current year.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research downgraded ICON PLC from a “buy” rating to a “hold” rating in a research report on Friday. Jefferies Group LLC reaffirmed a “buy” rating and set a $122.00 price target on shares of ICON PLC in a research report on Tuesday. Bank of America Corporation assumed coverage on ICON PLC in a research report on Monday, September 11th. They set a “buy” rating and a $128.00 price target on the stock. ValuEngine raised ICON PLC from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Finally, BidaskClub raised ICON PLC from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $113.67.
COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/16/strategic-global-advisors-llc-acquires-new-position-in-icon-plc-iclr.html.
ICON PLC Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICON PLC (NASDAQ:ICLR).
Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with MarketBeat.com's FREE daily email newsletter.